Sunday, February 1, 2026
17.9 C
Bengaluru

Indian Pharma Regional Performance Analysis & Summary

Overall Market Performance (IPM)
• The Indian Pharmaceutical Market (IPM) recorded a total value of ₹229,260.6 crore, with an overall growth of 7.6% for Dec’24.
• Out of 26 regions, 12 states/regions grew faster than the IPM growth rate of 7.6%, while the rest grew equal to or slower.

Regional Zone-Wise Performance
1. North Zone (₹62,928.3 Cr, 27% MS, 8.0% Growth)
• Top Contributors: Uttar Pradesh (₹25,550.2 Cr, 41% MS), Delhi (₹10,756.3 Cr, 17% MS).
• Fastest Growing: Delhi (12.5%), Jammu & Kashmir (9.4%), Haryana (8.8%).
2. South Zone (₹60,758.9 Cr, 27% MS, 7.1% Growth)
• Top Contributors: Karnataka (₹13,486.8 Cr, 22% MS), Tamil Nadu (₹11,509.0 Cr, 19% MS).
• Fastest Growing: Chennai (11.6%), Telangana (8.9%), Tamil Nadu (8.2%).
3. East Zone (₹56,501.1 Cr, 25% MS, 7.4% Growth)
• Top Contributors: West Bengal (₹14,651.3 Cr, 26% MS), Bihar (₹12,078.9 Cr, 21% MS).
• Fastest Growing: Chhattisgarh (9.5%), Orissa (8.7%), Assam (7.6%).
4. West Zone (₹49,072.3 Cr, 21% MS, 8.0% Growth)
• Top Contributors: Maharashtra (₹19,780.5 Cr, 40% MS), Madhya Pradesh (₹10,154.7 Cr, 21% MS).
• Fastest Growing: Madhya Pradesh (9.8%), Maharashtra (8.6%), Gujarat (8.7%).

Key Highlights

✅ Fastest Growing State: Delhi (12.5%)
✅ Other High Growth Regions: Chennai (11.6%), Madhya Pradesh (9.8%)
✅ Largest Market Share Contributors: Uttar Pradesh (₹25,550.2 Cr, 41% MS), Maharashtra (₹19,780.5 Cr, 40% MS), and West Bengal (₹14,651.3 Cr, 26% MS).
✅ North and West Zones had the highest growth rate (8.0%), while the South Zone had the slowest (7.1%).

Conclusion
• Delhi, Chennai, and Madhya Pradesh were the fastest-growing states.
• North and West zones led in growth, while the South zone expanded relatively slower.
• Key markets like Uttar Pradesh, Maharashtra, and West Bengal dominate market share.
• Overall, 12 states/regions outpaced the IPM growth rate of 7.6%, showing strong market potential.

Data Source: IQVIA

Hot this week

Quality, Not Price: Why the Generic Drug Debate Keeps Missing the Point

In an earlier article in The Wire Science, I...

IQVIA vs. PharmaTrac: Indian Pharma Market Data

Here is an analytical blog comparing the IQVIA MFR...

Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead

The latest PharmaTrac report for December 2025 offers a...

Orphan Drugs and Indian Pharma: Moving from Volume to Value?

Zydus’ ZYCUBO May Be the Proof Point the Industry...

Arjun Arunachalam: The Man Who Deleted Helium

For more than fifty years, the MRI industry treated...

Topics

IQVIA vs. PharmaTrac: Indian Pharma Market Data

Here is an analytical blog comparing the IQVIA MFR...

Orphan Drugs and Indian Pharma: Moving from Volume to Value?

Zydus’ ZYCUBO May Be the Proof Point the Industry...

Arjun Arunachalam: The Man Who Deleted Helium

For more than fifty years, the MRI industry treated...

Who Is Monitoring Quality in India’s Small Drug Units?

The Telangana Drugs Control Administration’s stop-use notice on a...

Zydus vs. Helsinn — What It Really Means for Indian Pharma

On December 24, 2025, the Delhi High Court delivered...

Worldclass Healthcare But Out of Reach for Most Indians?

When an eminent cardiologist like Dr. Sunil Chandy—former Director...
spot_img

Related Articles

spot_imgspot_img